We interviewed Dr. med. Bettina Bergtholdt, the Executive Manager (CEO) of emovis. She shared the company’s origin story with us and told us all about her entrepreneurial journey that began over two decades ago. She also told us about the exciting developments at emovis and about the evolution of the emovis Decentralized Clinical Trials Department. So, what is the big news at emovis? Read this interview to find out more!

We are excited to announce the sale of emovis to FutureMeds, a fast-growing independent European Dedicated Research Site Network that supports pharmaceutical companies, sponsors, and CROs. The fusion of FutureMeds' transformational, fully-owned dedicated research site network model with our proven solutions and expertise promises to bring about clinical trial solutions that will foster stronger partnerships with clients through even higher performance, efficiency, and quality.

We interviewed Rebeca González Vicedo, the Director of our Decentralized Clinical Trials Department, to learn about her work. Read this interview to find out about her interesting insights on Decentralized Clinical Trials (DCTs) and which unique perspectives emovis has combined to offer its comprehensive DCT service.

Mit etwa 95 Prozent aller Fälle ist erblich bedingter Haarausfall die häufigste Form von übermäßigem Haarverlust. Was ist seine Ursache? Wie äußert er sich? Welche Behandlungsmöglichkeiten gibt es? Das und vieles mehr erfahren Sie in diesem Beitrag.

Renée Werner took a moment to talk to us about her experience with thyroid cancer. Naturally, living with cancer at any age is life-transforming. In Renée’s case, it not only challenged her views about cancer as a disease, but also strengthened her belief in the good work being done in the clinical trial industry and all the great individuals who contribute to its progress.

On 21.05.2023 we celebrate the World Day for Cultural Diversity for Dialogue and Development. This is an important day, not only at emovis, but for all companies that are home to a diverse workforce. Diversity should be a given, but it was a long struggle before people with different nationalities, genders, gender identities and ethnic origins were recognized. In this blog post, we address the benefits and challenges that diversity brings.

Decentralized Clinical Trials (DCTs) seem to be a popular topic in the clinical trial industry these days. Not only can they increase patient recruitment and retention, but they may also be the meeting point between high patient centricity and financial returns in clinical trials. The developments DCTs have experienced in recent years appear to be a culmination of catering to patient needs and their lifestyles, as well as environmental push factors, such as the COVID 19 pandemic. What’s even more important in the development of DCTs, is that many industry representatives don’t quite yet understand what DCTs are. This is in part due to the fact that they may not be aware of the definition of a DCT and because many new terms have arisen around DCTs, which are being used interchangeably. In reality, DCTs are not all that novel and emovis has been conducting hybrid studies for over 10 years now.